Lowest Price Guaranteed From USD 4,899
The prefilled syringe fill finish manufacturing market is estimated to be worth $931 million in 2020 and is expected to grow at CAGR of 11.9% during the forecast period. Among drug delivery devices, prefilled syringes represent one of the fastest growing primary packaging formats, which are also designed for dose administration. In fact, over the past ten years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in an increased consumption of prefilled syringes, by approximately three fold. The sustained preference for such products can be attributed to the fact that prefilled syringes are safe and easy-to-use, and current variants are designed with provisions to reduce dosing errors, the risk of occlusions, extravasation and phlebitis. Owing to the aforementioned benefits, several injectable drugs (such as Humira®, Enbrel®, Avastin®, PREVNAR 13®, ALPROLIX® and Benefix®), diluents and other products requiring parenteral administration, are packaged in prefilled syringes. In fact, over the past seven years, around 90 drugs have been approved in combination with prefilled syringes across different geographies, including the North America, Europe and Asia-Pacific. Moreover, several clinical-stage drugs are being evaluated in combination with prefilled syringes, across different phases of development.
Prefilled syringe fill finish manufacturing is considered to be one of the most crucial steps in the pharmaceutical production process. Proper prefilled syringe fill finish, carried out under aseptic conditions, is a necessity for not only maintaining pharmacological efficacy and quality, but also ensuring end user safety. The prefilled syringe fill finish manufacturing operation is considered complex as it requires close monitoring of both the syringe fill volume as well as the headspace between the liquid in the syringe and the bottom of the plunger. Additionally, the rise in complexity of small molecule APIs and the increasing diversity of biologic drugs have also contributed towards the demand for advanced aseptic fill / finish operations. A number of small-sized companies and some large companies have outsourced their fill / finish operations to contract service providers. According to the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, biomanufacturers have been shown to outsource over 30% of their fill / finish operations. With the increase in the demand for prefilled syringes, along with the growing complexity of fill / finish processes, the outsourcing of these operations is likely to increase further in the future. Currently, over 100 companies are actively providing fill / finish services for prefilled syringes. In order to cope up with the current and future market demand, service providers are actively investing in expanding their existing infrastructure and capabilities; companies are also expanding their client reach through service agreements in the past few years. Given that around 55% of drug candidates in the global R&D pipeline are injectables, the opportunities for prefilled syringe developers / manufacturers and affiliated service providers is anticipated to continue to grow over the next decade. In addition, owing to the recent COVID-19 pandemic, an increase in the development initiatives for the vaccines is likely to be witnessed in the near future. This is expected to significantly raise the demand for prefilled syringes, providing an additional impetus to the overall prefilled syringe fill finish manufacturing market. Owing to this, the market is likely to witness substantial market growth during the forecast period.
Examples of key companies engaged in providing fill finish services for prefilled syringes market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Ajinomoto Bio-Pharma Services, AMRI, BioPharma Solutions, Emergent BioSolutions, Patheon (a Thermo Fisher Scientific Company), Consort Medical, EVER Pharma, GlaxoSmithKline, IDT Biologika, Rentschler Biopharma, Siegfried, Vetter Pharma, Biocon, Intas Pharmaceuticals, Kemwell Biopharma and Square Pharmaceuticals. This market report includes an easily searchable excel database of all the contract service providers for prefilled syringe fill / finish, worldwide.
Several recent developments have taken place in the field of prefilled syringe fill finish manufacturing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Prefilled Syringe Fill Finish Manufacturing Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the prefilled syringe fill finish manufacturing market. The market research report features an in-depth analysis of the key drivers and trends related to prefilled syringe fill finish manufacturing market.
Amongst other elements, the market research report includes:
The key objective of prefilled syringe fill finish manufacturing market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for prefilled syringe fill finish manufacturing market during the forecast period. Based on parameters, such as growth of the overall pharmaceutical and biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs, and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time forecast period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (preclinical, clinical and commercial), [B] key geographical regions (North America (the US), Europe (the UK, France, Italy, Spain, Germany and rest of Europe), Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina and Rest of Latin America), Middle East and Africa (Saudi Arabia, UAE, Africa and Rest of MEA)), [C] type of drug molecule (small molecule and biologic), [D] key therapeutic areas (blood disorders, infectious diseases, metabolic disorders, oncological disorders, neurological disorders, autoimmune disorders and others), [E] syringe barrel material (glass and plastic) and [F] number of barrel chambers (single chamber and dual chamber). To account for the uncertainties associated with the fill / finish of prefilled syringes and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.